|
You need to download the latest version of the Flash player.
|
 |
SERVICES |
|
| |
|
Trial Designs:
- Bioavailability/bioequivalence
- QT/ Interval
- First Time in Man
- Safety and tolerance
- Pharmacokinetics/Pharmacodynamics
- Phenotyping/Slow metabolizers
- Drug interactions
- Food-Intake/Food Effect
- Renal Function biomarkers
- Metabolic balance
- Phase I-IV
- SAD / MAD
|
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
|
| |
Additional Services:
- Protocol Design and Development
- Regulatory services (Central IRB)
- Source documentation creation
- CRF creation
- Data Management (Manual, Remote, Electronic data capture/transfers)
- Subject Recruitment
- Summary Reports
|
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
| |
From site assessment to trial closeout our commitment to your success starts from the first conversation. Although we are grateful for consideration of your trial needs, we want to be sure Prism Research is the right fit for your project. Honest protocol review and site assessment continues to be a process undervalued. Prism Research believes the up front communication process to be the most critical to ensuring trial success. Our management team will quickly evaluate your trial to determine if our team can meet your enrollment timelines and resources required for trial success. |
|
|
|
| |
RECRUITMENT / VOLUNTEER DEMOGRAPHICS
|
| |
- Healthy volunteers male / female
- Healthy seniors
- Epilepsy
- Renal Disease
- Type II Diabetes
- Hepatic disease
- Healthy Obese
- HIV
|
| |
Prism Research recognizes the need to continually augment volunteer database populations. Through a multi-faceted enrollment process that includes a dedicated recruitment department, collaborative physician partnerships, advertising and subject referral programs, Prism Research can deliver phase I results in the above populations. |
| |
|
| |
|
| |
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
| |
. Copyright © Prism Research, Inc. All Rights Reserved | PRIVACY POLICY |
|
| |
|
|
|
|
|
|
|
|
| |
|
|
